(Continuation news of SILVAPHL): During the period from July 1, 2025 to March 31, 2026, the Company's Net Profit after Tax and EPS decreased compared to the same period of the previous year, primarily due to a decline in sales volume. NOCFPS also decreased during the period, mainly attributable to lower sales and reduced collections from receivables. Furthermore, NAVPS per share declined as a result of the net loss incurred during the period. (end)

The Company has further informed that the meeting of the Board of Directors of the Company as per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on April 30, 2026 at 2:30 pm instead of earlier declared April 28, 2026 at 4:30 pm to consider, among others, Un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2026.

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2026 at 4:30 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.

Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of February 28, 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Silva%20Pharmaceuticals_2026.pdf

Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of ended 31 December, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Silva%20Pharma_25.pdf

(Cont. News of SILVAPHL): Reasons for deviation: EPS has decreased due to the decline in sales volume. NOCFPS has decreased compared to the same period of the previous year due to a decrease in the collection from receivables as well as sales. NAVPS has decreased due to net loss incurred during this period. (end)

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2026 at 3:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.

Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month ended 30 November, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/SIlva_2025.pdf

Credit Rating Agency of Bangladesh Limited (CRAB) has assigned Surveillance entity rating of the Company as "BBB1" and "ST-1" in the short term along with Stable outlook based on audited financial statements (FYE 30/06/2025, 30/06/2024, 30/06/2023), bank liability as on 30/11/2025 and other information up to the date of rating declaration.

The auditor of the company has given the Qualified Opinion in the audited financial statements of the company for the year ended June 30, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Silva%20Pharmaceuticals%20Limited_2025.pdf